Latest On Roche Holding AG (RHHBF):
| Date/Time | Type | Description | Signal | Details |
|---|---|---|---|---|
| 2024-03-14 06:01 EST | Dividend | A dividend of $9.6 has been announced on Feb 1, 2024. It will be paid Mar 18, 2024 with an ex-dividend date of Mar 14, 2024. | Neutral |  |
| 2023-05-26 18:42 EST | News | Roche withdraws filing for eye implant Susvimo for wet AMD in EU | N/A | |
| 2023-05-26 04:04 EST | News | Roche, With Ocrevus And Fenebrutinib Advancement, Should Be Top MS Contender | N/A | |
| 2023-05-17 10:15 EST | News | Roche MS drug reduces brain lesions, meeting goals of phase 2 trial | N/A | |
| 2023-05-09 06:05 EST | News | Roche's eye therapy Vabysmo gets FDA review for expanded use | N/A | |
| 2023-05-04 18:40 EST | News | Roche launches Institute of Human Biology for research on organoids | N/A | |
| 2023-04-28 12:58 EST | News | Roche: Q1 Results Support Our Long-Term Thesis | N/A | |
| 2023-04-28 12:58 EST | News | Roche's COVID therapy Ronapreve gets EMA greenlight for expanded use in EU | N/A | |
| 2023-04-28 12:58 EST | News | Tempest surges ~40% as TPST-1120 shows promise in liver cancer trial | N/A | |
| 2023-04-27 12:03 EST | News | Roche's blood cancer drug Columvi gets EMA panel nod for EU approval | N/A | |
| 2023-04-26 23:42 EST | News | Roche Holding AG (RHHBY) Q1 2023 Earnings Call Transcript | N/A | |
| 2023-04-26 11:33 EST | News | Roche's new eye drug shines amid COVID products pulling down Q1 sales; affirms outlook | N/A | |
| 2023-04-20 15:27 EST | News | Roche's Polivy combo wins FDA approval to treat blood cancer subtype | N/A | |
| 2023-03-22 19:34 EST | News | Lilly, Roche team up to develop blood test for Alzheimer's disease | N/A | |
| 2023-03-22 19:34 EST | News | Roche: A Bitter Pill It Needs To Swallow | N/A | |
| 2023-03-16 09:59 EST | News | Roche new CEO takes over as former head transitions to Chairman role | N/A | |
| 2023-03-16 05:56 EST | Dividend | A dividend of $9.5 has been announced on Feb 2, 2023. It will be paid Mar 20, 2023 with an ex-dividend date of Mar 16, 2023. | Neutral | |
| 2023-03-10 15:52 EST | News | Roche gets FDA panel nod for Polivy as initial therapy for large B-cell lymphoma | N/A | |
| 2023-03-01 18:37 EST | News | Roche's Genentech sues Biogen over additional patent royalties from Tysabri sales | N/A | |
| 2023-02-27 21:43 EST | News | Roche upped to buy at Societe Generale on P/E discount, R&D track record | N/A | |
| 2023-02-23 21:35 EST | News | Blueprint Medicines, Roche end partnership for cancer medicine | N/A | |
| 2023-02-23 08:04 EST | News | Roche launches 2 new antibodies to detect mutations in brain cancer | N/A | |
| 2023-02-15 17:44 EST | News | Roche: What To Make Of The Massive Insider Sale And 2022 Earnings | N/A | |
| 2023-02-13 13:10 EST | News | Hookipa Pharma gets $10M milestone payment from Roche | N/A | |
| 2023-02-10 06:46 EST | News | Roche Vabysmo matches Eylea in 2 phase 3 trials for eye disorder | N/A | |
| 2023-02-09 17:45 EST | News | Roche, Janssen Biotech partner to develop companion diagnostics | N/A | |
| 2023-02-07 12:29 EST | News | Roche's less frequently dosed crovalimab matches Soliris, meets phase 3 trial goals in rare blood disorder | N/A | |
| 2023-02-03 01:25 EST | News | Roche Holding AG (RHHBY) Q4 2022 Earnings Call Transcript | N/A | |
| 2023-02-03 01:25 EST | News | Roche: Lower Guidance In 2023, But Positive Trajectory | N/A | |
| 2023-02-02 11:20 EST | News | Roche Holding Non-GAAP EPS of CHF20.30, revenue of CHF63.28B | N/A | |
| 2023-02-02 11:20 EST | News | Roche sees fall in FY23 earnings on 'sharp decline' in COVID products sales | N/A | |
| 2023-02-02 11:20 EST | News | Roche's hemophilia A therapy Hemlibra gets approval in EU for expanded use | N/A | |
| 2023-01-26 14:01 EST | News | Roche launches test to detect fast spreading Omicron sub-variant XBB.1.5 | N/A | |
| 2023-01-25 09:53 EST | News | Roche, Sysnav team up on movement tracking tech for neuromuscular disorders | N/A | |
| 2023-01-19 12:14 EST | News | Roche's Tecentriq, Avastin combo cuts risk of liver cancer returning, in phase 3 trial | N/A | |
| 2023-01-13 03:49 EST | News | Tamiflu supplies released from national stockpile as nationwide shortage persists | N/A | |
| 2023-01-12 16:00 EST | News | Roche influenza therapy Xofluza gets approval in EU for use in children | N/A | |
| 2023-01-11 16:14 EST | News | Johnson & Johnson Is A Better Dividend Stock Than Roche, Despite A 20% Lower Yield | N/A | |
| 2023-01-06 05:14 EST | News | Roche's new immunotherapy glofitamab gets FDA priority review for blood cancer subtype | N/A | |
| 2022-12-29 10:23 EST | News | Pfizer says hemophilia B gene therapy met key goal in Phase 3 trial | N/A | |
| 2022-12-23 16:21 EST | News | Roche Lunsumio for blood cancer subtype gets FDA approval | N/A | |
| 2022-12-22 05:58 EST | News | Roche's Actemra granted FDA approval for COVID-19 | N/A | |
| 2022-12-17 22:50 EST | News | It's almost 2023, but here are the drugs the FDA could approve before the end of the year | N/A | |
| 2022-12-17 06:13 EST | News | Roche (RHHBY) Presents at 64th ASH Annual Meeting & Exposition | N/A | |
| 2022-12-16 12:31 EST | News | Roche's hemophilia A therapy Hemlibra's expanded use gets EMA panel's backing | N/A | |
| 2022-12-14 07:57 EST | News | Roche, Pfizer team up in US for COVID awareness campaign | N/A | |
| 2022-12-12 22:10 EST | News | Roche pharma head to leave by year-end | N/A | |
| 2022-12-08 16:42 EST | News | Roche Alzheimer's disease cerebrospinal fluid tests get FDA nod | N/A | |
| 2022-12-07 23:19 EST | News | Replimune in pact with Roche to study cancer drug combos | N/A | |
| 2022-12-01 20:24 EST | News | Roche to stop studies of gantenerumab in early Alzheimer's after trials fail | N/A | |
About Roche Holding AG (RHHBF):
Roche Holding AG engages in the prescription pharmaceuticals and diagnostics businesses in Switzerland, Germany, and internationally. It offers pharmaceutical products for treating anemia, cancer, cardiovascular, central nervous system, dermatology, hepatitis B and C, HIV/AIDS, inflammatory and autoimmune, intensive care medicine, leukemia, lymphoma, metabolic disorders, ophthalmology, respiratory disorders, rheumatoid arthritis, skin cancer, and transplantation. The company also offers in vitro diagnostics solutions for indications, such as cardiology, hematology, blood donor screening, coagulation, infectious disease, gynecology, oncology, and women's health. In addition, it supplies diagnostic instruments, reagents, consumables, and test kits for use in the diverse research market. Roche Holding AG has collaboration with Gilead Sciences, Inc. for COVID-19; a license and collaboration agreement with Shionogi & Co., Ltd. to develop and commercialize Xofluza; and has collaboration with Affimed N.V to study AFM24 in combination with PD-L1 checkpoint inhibitor in EGFR expressing solid tumors. The company was founded in 1896 and is headquartered in Basel, Switzerland.
General
- Name Roche Holding AG
- Symbol RHHBF
- Type Common Stock
- Exchange OTCQX
- Currency USD
- Country USA
- SectorHealthcare
- IndustryDrug Manufacturers-General
- Full Time Employees 101,465
- Fiscal Year EndDecember
- Web URLhttp://www.roche.com
Valuation
- Trailing PE 28.05
- Forward PE 15.53
- Price/Sales (Trailing 12 Mt.) 4.77
- Price/Book (Most Recent Quarter) 7.55
- Enterprise Value Revenue 5.01
- Enterprise Value EBITDA 12.67
Financials
- Most Recent Quarter 2020-12-31
- Profit Margin 24%
- Return on Assets 15%
- Return on Equity 40%
- Earnings Per Share $12.28
- Revenue Per Share $0
- Gross Profit 44.48 billion
- Quarterly Earnings Growth -6.4%
Highlights
- Market Capitalization 283.82 billion
- PE Ratio 2.08
- PEG Ratio 3.07
- Book Value Per Share $32.31
Share Statistics
- Shares Outstanding 160 million
- Shares Float 719.13 million
- % Held by Insiders 8355%
- % Held by Institutions 4.04%
Technicals
- Beta 0.21
- 52 Week High $378.1
- 52 Week Low $270
- 50 Day Moving Average 349.35
- 200 Day Moving Average 347.9
Dividends
- Forward Annual Dividend Rate $10.12
- Forward Annual Dividend Yield 2.87%
- Payout Ratio 72%
- Dividend Date 2015-03-10
- ExDividend Date 2021-03-18
- Dividend Per Share $8.38
- Dividend Yield 0%
Roche Holding AG (RHHBF) Dividend Calendar:
RHHBF's last dividend payment was made to shareholders on March 10, 2015.
Roche Holding AG pays out 72% of its earnings out as a dividend.
| Ex-Dividend Date | Payment Date | Record Date | Declared Date | Amount |
|---|
Roche Holding AG (RHHBF) Earnings History:
Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.
| Quarter Date | Report Date | Actual Revenue | Reported EPS | EPS Estimate | Deviation from Estimate |
|---|---|---|---|---|---|
| 2020-09-30 | 2020-12-31 | $N/A | $4.06 | $0.00 | |
| 2020-06-30 | 2020-09-30 | $N/A | $3.90 | $0.00 | |
| 2020-03-31 | 2020-06-30 | $N/A | $4.92 | $0.00 | |
| 2019-12-31 | 2020-03-31 | $16.53 billion | $4.85 | $0.00 | |
| 2019-09-30 | 2019-12-31 | $16.03 billion | $2.91 | $0.00 | |
| 2019-06-30 | 2019-09-30 | $16.22 billion | $2.82 | $0.00 | |
| 2019-03-31 | 2019-06-30 | $15.89 billion | $5.11 | $0.00 | |
| 2018-12-31 | 2019-03-31 | $15.27 billion | $5.01 | $0.00 | |
| 2018-09-30 | 2018-12-31 | $15.23 billion | $1.89 | $0.00 | |
| 2018-06-30 | 2018-09-30 | $14.86 billion | $1.89 | $0.00 | |
| 2018-03-31 | 2018-06-30 | $15.45 billion | $4.30 | $0.00 | |
| 2017-12-31 | 2018-03-31 | $14.47 billion | $4.46 | $0.00 | |
| 2017-09-30 | 2017-12-31 | $14.47 billion | $1.88 | $0.00 | |
| 2017-06-30 | 2017-09-30 | $13.77 billion | $1.89 | $0.00 | |
| 2017-03-31 | 2017-06-30 | $13.77 billion | $3.32 | $0.00 | |
| 2016-12-31 | 2017-03-31 | $3.18 | $0.00 | ||
| 2016-09-30 | 2016-12-31 | $2.40 | $0.00 | ||
| 2016-06-30 | 2016-09-30 | $2.52 | $0.00 | ||
| 2016-03-31 | 2016-06-30 | $3.20 | $0.00 | ||
| 2015-12-31 | 2016-03-31 | $3.26 | $0.00 | ||
| 2015-09-30 | 2015-12-31 | $2.15 | $0.00 | ||
| 2015-06-30 | 2015-09-30 | $2.20 | $0.00 | ||
| 2015-03-31 | 2015-06-30 | $3.19 | $0.00 | ||
| 2014-12-31 | 2015-03-31 | $3.08 | $0.00 | ||
| 2014-09-30 | 2014-12-31 | $2.22 | $0.00 | ||
| 2014-06-30 | 2014-09-30 | $2.30 | $0.00 | ||
| 2014-03-31 | 2014-06-30 | $3.61 | $0.00 | ||
| 2013-12-31 | 2014-03-31 | $3.63 | $0.00 | ||
| 2013-09-30 | 2013-12-31 | $3.40 | $0.00 | ||
| 2013-06-30 | 2013-09-30 | $3.35 | $0.00 | ||
| 2013-03-31 | 2013-06-30 | $3.63 | $0.00 | ||
| 2012-12-31 | 2013-03-31 | $3.62 | $0.00 | ||
| 2012-09-30 | 2012-12-31 | $3.33 | $0.00 | ||
| 2012-06-30 | 2012-09-30 | $3.24 | $0.00 | ||
| 2012-03-31 | 2012-06-30 | $2.60 | $0.00 | ||
| 2011-12-31 | 2012-03-31 | $2.73 | $0.00 | ||
| 2011-09-30 | 2011-12-31 | $2.64 | $0.00 | ||
| 2011-06-30 | 2011-09-30 | $2.73 | $0.00 | ||
| 2011-03-31 | 2011-06-30 | $3.59 | $0.00 | ||
| 2010-12-31 | 2011-03-31 | $3.30 | $0.00 | ||
| 2010-09-30 | 2010-12-31 | $2.00 | $0.00 |
Roche Holding AG (RHHBF) Company Financial Statements:
Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.
Income Statement:
| Date |
|---|
| Research Development |
| Income Before Tax |
| Selling General Administrative |
| Gross Profit |
| Ebit |
| Operating Income |
| Income Tax Expense |
| Total Revenue |
| Cost of Revenue |
| Total Other Income Expense Net |
| Net Income From Continuing Operations |
| Net Income Applicable to Common Shares |
Cash Flow:
| Date |
|---|
| Investments |
| Change to Liabilities |
| Total Cash Flow from Investing Activities |
| Net Borrowings |
| Total Cash Flow from Financial Activities |
| Change to Operating Activities |
| Change in Cash |
| Total Cash from Operating Activities |
| Depreciation |
| Other Cash Flow from Investing Activities |
| Change to Inventory |
| Change to Account Receivables |
| Other Cash Flow from Financing Activities |
| Change to Net Income |
| Capital Expenditures |
Balance Sheet:
| Date |
|---|
| Total Liabailities |
| Total Stockholder Equity |
| Other Current Liabilities |
| Total Assets |
| Common Stock |
| Other Current Assets |
| Retained Earnings |
| Other Liabilities |
| Other Assets |
| Cash |
| Total Current Liabilities |
| Other Stockholder Equity |
| Property, Plant & Equipment |
| Total Current Assets |
| Long Term Investments |
| Net Tangible Assets |
| Short Term Investments |
| Long Term Debt |
| Inventory |
| Accounts Payable |
Roche Holding AG (RHHBF) Chart:
Roche Holding AG (RHHBF) News:
Below you will find a list of latest news for Roche Holding AG (RHHBF) from major news sources. You can filter the results to only show news from a specific source.
No recent news available
Roche Holding AG (RHHBF) Options:
A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.
| Expiration Date | Strike | Last Price | Type | Volume | Open Interest | Implied Volatility | In The Money | Change | Change Percent |
|---|
Roche Holding AG (RHHBF) SEC Filings:
An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.
| Date | Form Type | Form Name | Link |
|---|